CCL2 and neoplasm: Bindarit is a small molecule drug that inhibits the synthesis of CCL2 and has been shown to induce tumor regression in preclinical studies by inhibiting TAM and MDSC infiltration of the TME in breast cancer, prostate cancer, and osteosarcoma animal models (126–129).